Delivery Order SPE2DB22D9304-SPE2DB25FSTA4
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,273.32 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/mL auto-injector units. The delivery order, awarded on August 15, 2025, with an ultimate completion date of September 8, 2025, utilizes firm fixed-price pricing and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's...
- The Defense Logistics Agency awarded a delivery order valued at $10,273.38 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector units. This firm fixed-price delivery order, awarded on August 14, 2025, with an ultimate completion date of September 5, 2025, represents a specific fulfillment under the company's larger Indefinite Delivery Contract with DLA valued at $499,999,999...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $1,712.22 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of Xolair 150 mg/ml autoinjectors, with a period of performance through October 3, 2024. This delivery order is issued under DMS Pharmaceutical Group's existing indefinite delivery contract (IDC) with the DLA, valued at up to...
- The Defense Logistics Agency awarded a delivery order valued at $27,395.68 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 mL auto-injector medications. This firm fixed-price delivery order was issued on August 19, 2025, with an ultimate completion date of September 10, 2025, and does not utilize a set-aside designation. The award represents a specific fulfillment under DMS Pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $1,712.23 to DMS Pharmaceutical Group Inc. for the supply of Xolair 300 mg/2 ml auto-injector vials. This firm fixed-price delivery order, issued on August 19, 2025, is scheduled for completion by September 10, 2025, with performance taking place in Park Ridge, Illinois. The contract utilizes no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, holds a...
- The Defense Logistics Agency awarded a $20,546.76 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for 300 mg/2 mL Xolair (omalizumab) auto-injector units with an ultimate completion date of September 15, 2025. This award was issued without a set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected as the prime contractor. Xolair is a biologic medication used primarily for treating...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $3,424.46 by the Defense Logistics Agency on August 19, 2025. The contract calls for the delivery of Xolair 300 mg/2 ml auto-injector vials, a biologic medication used primarily for severe asthma and other allergic conditions. This delivery order was issued without a set-aside designation, and performance is scheduled for...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $1,712.23 to DMS Pharmaceutical Group Inc. for the supply of Xolair 300 mg/2 mL auto-injector vials. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will deliver the product to the same location by the ultimate completion date of September 3, 2025. This delivery order was issued without a set-aside designation and is part of DMS Pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector vials. The delivery order, valued at $6,848.92 with a firm fixed price arrangement, is scheduled for completion by September 9, 2025, and was issued on August 18, 2025. This award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete directly in...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on August 20, 2025, for the supply of Xolair 300 mg/2 ml auto-injector vials. The contract has a ceiling value of $85,611.50 with an ultimate completion date of September 11, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing...
- SPE2DB22D9304Indefinite Delivery Contract
- SPE2DB22D9304-SPE2DB25FSTA4Delivery Order
The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector vials. This firm fixed-price delivery order, valued at $1,712.23, was executed on August 22, 2025, with an ultimate completion date of September 15, 2025. The award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on a full-and-open basis within the federal procurement marketplace. This delivery order is issued under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with the Defense Logistics Agency valued at approximately $500 million through November 2026. The IDC enables the agency to procure a comprehensive portfolio of pharmaceutical products, including prescription medications, biologics, and medical consumables for Department of Defense healthcare facilities. Xolair, a biologic medication for treating allergic asthma and chronic urticaria, represents one component of the company's extensive pharmaceutical distribution services supporting military health operations nationwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 8/22/25 |